Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Qian, Yichun ^a,b   Qiu, Mantang ^a,b   Wu, Qingquan ^b   Tian, Yanyan ^c   Zhang, Yu ^c   Gu, Ning ^c   Li, Suyi ^d   Xu, Lin ^a   Yin, Rong ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Southeast University   (China)

^d AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GOLD; METAL NANOPARTICLE; MONOCLONAL ANTIBODY;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CETUXIMAB; FLOW CYTOMETRY; GOLD; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; METAL NANOPARTICLES; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924947966     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07490     Document Type: Article

References (26)

1. Ahmad, M. Z. et al.Nanometric gold in cancer nanotechnology: current status and future prospect. J Pharm Pharmacol. 65, 634-651 (2013).
2. Joseph, M. M., Aravind, S. R., Varghese, S., Mini, S. & Sreelekha, T. T. PST-Gold nanoparticle as an effective anticancer agent with immunomodulatory properties. Colloids Surf B Biointerfaces. 104, 32-39 (2013).
3. Kao, H. W. et al. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett. 23, 3180-3185 (2013).
4. Lan, M. Y. et al. Induction of apoptosis by high-dose gold nanoparticles in nasopharyngeal carcinoma cells. Auris Nasus Larynx. 40, 563-568 (2013).
5. Curley, S. A. et al. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol. 7, 313-326 (2008).
6. Pirker, R. EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol. 8, 47-53 (2013).
7. Leung, L., Mok, T. S. & Loong, H. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Ther Adv Med Oncol. 4, 173-181 (2012).
8. Ryu, S. H. et al. Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines. Lung Cancer. 77, 482-487 (2012).
9. Khan, J. A. et al. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 6, e20347 (2011).
10. Khambata-Ford, S. et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/ carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 28, 918-927 (2010).
11. Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 47, 1231-1243 (2011).
12. Hainfeld, J. F. et al. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br J Radiol. 84, 526-533 (2011).
13. Webster, D. M., Sundaram, P. & Byrne, M. E. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm. 84, 1-20 (2013).
14. Chao, X. et al. A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy. PLoS One. 7, e40388 (2011).
15. Liu, X. et al. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS Nano. 7, 6244-6257 (2013).
16. Kutty, R. V. & Feng, S. S. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials. 34, 10160-10171 (2013).
17. Ettinger, D. S. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist. 11, 358-373. (2006)
18. Chen, Y. H. et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm. 4, 713-722 (2007).
19. Huang, S. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824-833 (2013).
20. Wu, Y. N. et al. The anticancer properties of iron core-gold shell nanoparticles in colorectal cancer cells. Int J Nanomedicine. 8, 3321-3331 (2013).
21. Brown, S. D. et al.Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 132, 4678-4684 (2013).
22. Pan, Y. et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small. 5, 2067-2076 (2009).
23. Prabaharan, M., Grailer, J. J., Pilla, S., Steeber, D. A. & Gong, S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials. 30, 6065-6075 (2009).
24. Takata, M. et al. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biol Ther. 13, 369-378 (2012).
25. Mukherjee, P. et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 11, 3530-3534 (2005).
26. Bhattacharyya, S. et al. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci USA 33, 14541-14546 (2010).